StockData

Pyxis Oncology vs Zentalis Pharmaceuticals

PYXS and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PYXS and ZNTL compare

Pyxis Oncology and Zentalis Pharmaceuticals are about the same size, with market caps of $120M and $107M.

Zentalis Pharmaceuticals scores higher on the StockData Score (6 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPYXSZNTL
Size and price
Market cap$120M$107M
Share price$1.44$1.49
Change, 1 year−67.0%12.0%
Change, 5 years−88.8%−98.0%
Beta (5Y)3.155.80
Employees56106
StockData Score
Total score56 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score55
Dividend score00
Valuation
P/B10.5×0.7× (better)
FCF yield–−120%
Profitability
Return on equity−179%−66.7% (better)
Financial health
Debt / equity0.000.00
Current ratio1.344.82 (better)
Altman Z-score−16.21−8.91 (better)
Piotroski F-score11
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions40.9%66.1%
Held by insiders20.4%58.0%
Insider net buying, 12 months−$107K$12.8M (better)
Short interest, % of float6.8%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.